Physician profile
James Demos
NPI 1457353872
$3,150.52
in general payments reported to CMS, 2019-2025
28 companies · $741 in 2025
The $741 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $404 · 2021: $308 · 2022: $136 · 2023: $254 · 2024: $690 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $573.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $508.16 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $281.10 | 2019-2025 | Linzess |
| Pfizer INC. | $209.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $182.60 | 2020-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $178.32 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $157.97 | 2023-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $155.39 | 2019-2022 | |
| Amarin Pharma, INC. | $142.21 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.07 | 2021-2025 | Jardiance |
| Allergan, INC. | $98.75 | 2019-2020 | |
| Lilly USA, LLC | $80.82 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $70.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.42 | 2024-2025 | |
| Abbott Laboratories | $60.27 | 2021-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $43.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.27 | 2019 | |
| Dynavax Technologies Corporation | $22.40 | 2024 | Heplisav-B |
| Krystal Biotech INC | $21.20 | 2024 | Vyjuvek |
| Arbor Pharmaceuticals, INC. | $17.52 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.29 | 2024 | Fanapt, Hetlioz |
| Corcept Therapeutics | $15.53 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $15.09 | 2025 | |
| Sumitomo Pharma America, INC. | $14.78 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $13.64 | 2020 | |
| Medicure Pharma INC. | $13.47 | 2024 | Zypitamag |
| Nestle Healthcare Nutrition INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Demos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.